Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the cGAS-STING pathway for therapeutic gain in autoimmune inflammatory cutaneous diseases with a focus on systemic lupus erythematosus and systemic sclerosis.

The British journal of dermatology·2025
Same author

The Role of the Pulmonary Microenvironment in Driving Transition From Systemic Sclerosis to Systemic Sclerosis-Associated Interstitial Lung Disease.

The Journal of rheumatology·2025
Same author

A Long Stretch: IL-11 Drives Skin Regeneration.

The Journal of investigative dermatology·2025
Same author

Extracellular BAG3 is elevated in early diffuse systemic sclerosis.

Military Medical Research·2025
Same author

The metabolic drivers of IFN-γ release: glycolysis and acetyl CoA ride in the front seat.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Aberrant fumarate metabolism links interferon release in diffuse systemic sclerosis.

Journal of dermatological science·2025

Related Experiment Video

Updated: Apr 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K

miRNA-29a in systemic sclerosis: A valid target.

Steven O'Reilly1

  • 1a School of Biological and Biomedical Sciences, Durham University , Durham , UK.

Autoimmunity
|September 4, 2015
PubMed
Summary

Systemic sclerosis, an autoimmune disease, involves inflammation and fibrosis. Restoring microRNA-29a induces fibroblast apoptosis, offering a potential new treatment for this condition.

Area of Science:

  • Immunology
  • Fibrosis research
  • Autoimmune diseases

Background:

  • Systemic sclerosis is characterized by inflammation and fibrosis, driven by myofibroblasts producing excessive matrix molecules.
  • Current treatments for systemic sclerosis lack disease-modifying capabilities, highlighting a significant unmet clinical need.
  • Myofibroblasts are the key effector cells responsible for the fibrotic pathology in systemic sclerosis.

Discussion:

  • The study by Jafarinejad-Farsaangi et al. investigates the role of microRNA-29a in regulating fibroblast apoptosis.
  • Restoring microRNA-29a levels was shown to target the apoptosis rheostat in dermal fibroblasts.
  • This targeting leads to increased apoptosis, suggesting a mechanism for fibroblast depletion.

Key Insights:

  • MicroRNA-29a plays a crucial role in inducing apoptosis in dermal fibroblasts.
Keywords:
ApoptosisautoimmunefibrosismicroRNA-29asystemic sclerosis

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.2K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K

Related Experiment Videos

Last Updated: Apr 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.1K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.2K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
  • Targeting the apoptosis rheostat is a viable strategy for fibroblast depletion in systemic sclerosis.
  • Restitution of microRNA-29a offers a potential therapeutic avenue for systemic sclerosis.

    • Outlook:

    • In vivo administration of microRNA-29a mimics could deplete pathogenic fibroblasts.
    • This approach may lead to the development of novel disease-modifying therapies for systemic sclerosis.
    • Further research is warranted to translate these findings into clinical applications for treating systemic sclerosis.